CN101490086B - 来自ch5D12抗体的去免疫拮抗性抗人CD40单克隆抗体 - Google Patents

来自ch5D12抗体的去免疫拮抗性抗人CD40单克隆抗体 Download PDF

Info

Publication number
CN101490086B
CN101490086B CN200780025878.9A CN200780025878A CN101490086B CN 101490086 B CN101490086 B CN 101490086B CN 200780025878 A CN200780025878 A CN 200780025878A CN 101490086 B CN101490086 B CN 101490086B
Authority
CN
China
Prior art keywords
antibody
cells
cell
ch5d12
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200780025878.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN101490086A (zh
Inventor
M·T·登哈尔托赫
R·J·J·范内尔芬
K·S·约翰逊
R·D·卡松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diabetes Free Co
Original Assignee
Pangenetics BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pangenetics BV filed Critical Pangenetics BV
Publication of CN101490086A publication Critical patent/CN101490086A/zh
Application granted granted Critical
Publication of CN101490086B publication Critical patent/CN101490086B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN200780025878.9A 2006-05-09 2007-05-09 来自ch5D12抗体的去免疫拮抗性抗人CD40单克隆抗体 Active CN101490086B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79881906P 2006-05-09 2006-05-09
US60/798,819 2006-05-09
EP06076028.7 2006-05-09
EP06076028A EP1854810A1 (en) 2006-05-09 2006-05-09 Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
PCT/NL2007/050202 WO2007129895A2 (en) 2006-05-09 2007-05-09 Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody

Publications (2)

Publication Number Publication Date
CN101490086A CN101490086A (zh) 2009-07-22
CN101490086B true CN101490086B (zh) 2014-03-05

Family

ID=37635851

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780025878.9A Active CN101490086B (zh) 2006-05-09 2007-05-09 来自ch5D12抗体的去免疫拮抗性抗人CD40单克隆抗体

Country Status (20)

Country Link
US (1) US8669352B2 (enExample)
EP (2) EP1854810A1 (enExample)
JP (1) JP5179474B2 (enExample)
KR (1) KR101506348B1 (enExample)
CN (1) CN101490086B (enExample)
AR (1) AR060998A1 (enExample)
AU (1) AU2007249031B9 (enExample)
BR (1) BRPI0711355A2 (enExample)
CA (1) CA2651565A1 (enExample)
CL (1) CL2007001335A1 (enExample)
DK (1) DK2019840T3 (enExample)
ES (1) ES2406163T3 (enExample)
IL (1) IL195196A (enExample)
MX (1) MX2008014304A (enExample)
NO (1) NO20085104L (enExample)
NZ (1) NZ572756A (enExample)
RU (1) RU2491295C2 (enExample)
TW (1) TWI455947B (enExample)
WO (1) WO2007129895A2 (enExample)
ZA (2) ZA200810381B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5250548B2 (ja) 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体ｈ因子の標的化
ME01699B (me) 2009-07-02 2014-09-20 Musc Found For Res Dev Metode za stimulaciju regeneracije jetre
SI2462158T1 (en) 2009-08-06 2018-04-30 F. Hoffmann-La Roche Ag Method to improve virus removal in protein purification
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
AU2011235214B2 (en) * 2010-03-31 2015-04-23 Boehringer Ingelheim International Gmbh Anti-CD40 antibodies
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
PL2683406T3 (pl) 2011-03-11 2019-11-29 Beth Israel Deaconess Medical Ct Inc Przeciwciała anty-cd40 i ich zastosowania
PL2699601T3 (pl) 2011-04-21 2018-05-30 Bristol-Myers Squibb Company Polipeptydy przeciwciała, które antagonizują CD40
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CN105636984A (zh) * 2013-06-13 2016-06-01 法斯特弗沃德制药有限公司 用于治疗慢性炎症和预防胃肠道癌或纤维化的cd40信号转导抑制剂和其他化合物，该其他化合物是胆汁酸、胆汁酸衍生物、tgr5受体激动剂、fxr激动剂或其组合
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
EP3113796A1 (en) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
HUE054148T2 (hu) * 2014-08-07 2021-08-30 Daiichi Sankyo Co Ltd Anti-ORAI1 antitest
WO2016028810A1 (en) * 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
US9888673B2 (en) 2014-12-10 2018-02-13 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
HUE048284T2 (hu) 2015-05-29 2020-07-28 Abbvie Inc Anti-CD40 antitestek és alkalmazásuk
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
CN108368510B (zh) 2015-09-30 2023-09-01 詹森生物科技公司 特异性结合人cd40的激动性抗体和使用方法
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CA3055433A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Humanized anti-cd40 antibodies
CN110267989B (zh) 2017-06-01 2023-04-04 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途
KR20200074993A (ko) 2017-11-03 2020-06-25 노파르티스 아게 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체
EP3752532A1 (en) * 2018-02-12 2020-12-23 Diabetes-Free, Inc. Improved antagonistic anti-human cd40 monoclonal antibodies
BR112020020277A2 (pt) 2018-04-13 2021-01-19 Novartis Ag Anticorpos anti-cd40 para uso na prevenção de rejeição de enxerto
AU2019255781A1 (en) * 2018-04-20 2020-10-29 Lyvgen Biopharma Holdings Limited Anti-CD40 antibodies and uses thereof
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
CN116063495A (zh) 2018-09-28 2023-05-05 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
WO2020070288A1 (en) 2018-10-05 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
BR112021010414A2 (pt) 2018-11-30 2021-09-08 Jiangsu Hengrui Medicine Co., Ltd. Composição farmacêutica compreendendo um anticorpo cd40, método para preparar uma preparação liofilizada, preparação liofilizada, uso das mesmas e produto que compreende um recipiente contendo as mesmas
CN112969714B (zh) 2018-11-30 2022-11-22 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途
MX2021008305A (es) 2019-01-11 2021-08-24 Novartis Ag Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa.
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
CN113784985A (zh) 2019-05-08 2021-12-10 诺华股份有限公司 T1dm和胰岛炎的治疗中使用的抗cd40抗体
JP2022553493A (ja) 2019-09-11 2022-12-23 ノバルティス アーゲー 患者におけるヒトウイルス関連障害を予防するための方法
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
HRP20250696T1 (hr) 2021-01-28 2025-08-01 Regeneron Pharmaceuticals, Inc. Sastavi i postupci za liječenje sindroma oslobađanja citokina
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023020475A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Cd40-targetting antibodies and uses thereof
EP4393937A1 (en) 2021-08-26 2024-07-03 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
EP0651797B1 (en) 1992-07-09 2004-01-28 Chiron Corporation A method for generation of antibodies to cell surface molecules
EP0922111B1 (en) 1996-07-23 2004-12-01 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KASRAN,A. et al..Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn’s disease.《Aliment Pharmacol Ther》.2005,第22卷第111–122页. *
Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys;Louis Boon et al.;《Toxicology》;20020515;第174卷;第53-65页 *

Also Published As

Publication number Publication date
KR20090029203A (ko) 2009-03-20
KR101506348B1 (ko) 2015-04-08
ZA200810381B (en) 2010-03-31
HK1131627A1 (en) 2010-01-29
AU2007249031B9 (en) 2013-01-24
IL195196A (en) 2016-02-29
WO2007129895A2 (en) 2007-11-15
ZA200909185B (en) 2012-07-25
TWI455947B (zh) 2014-10-11
IL195196A0 (en) 2011-08-01
US8669352B2 (en) 2014-03-11
CA2651565A1 (en) 2007-11-15
NO20085104L (no) 2009-02-09
EP2019840A2 (en) 2009-02-04
BRPI0711355A2 (pt) 2011-09-27
MX2008014304A (es) 2008-11-26
AU2007249031B2 (en) 2012-09-27
ES2406163T3 (es) 2013-06-05
RU2491295C2 (ru) 2013-08-27
CN101490086A (zh) 2009-07-22
WO2007129895A3 (en) 2008-12-31
US20080085531A1 (en) 2008-04-10
TW200815471A (en) 2008-04-01
EP2019840B1 (en) 2012-12-19
JP2009536522A (ja) 2009-10-15
NZ572756A (en) 2012-10-26
DK2019840T3 (da) 2013-03-25
EP1854810A1 (en) 2007-11-14
AR060998A1 (es) 2008-07-30
RU2008148303A (ru) 2010-06-20
WO2007129895A9 (en) 2009-02-19
JP5179474B2 (ja) 2013-04-10
CL2007001335A1 (es) 2008-01-18
AU2007249031A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
CN101490086B (zh) 来自ch5D12抗体的去免疫拮抗性抗人CD40单克隆抗体
AU2006308860B2 (en) Uses of anti-CD40 antibodies
US11396552B2 (en) Antagonistic anti-human CD40 monoclonal antibodies
TW201125876A (en) Isolation and purification of anti-IL-13 antibodies using protein a affinity chromatography
JP2009019046A (ja) アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
US20110217319A1 (en) Methods of use of sialoadhesin factor-2 antibodies
AU2020414265A1 (en) Anti-human HVEM (TNFRSF14) antibodies and uses thereof
WO2001066126A1 (en) Sialoadhesin factor-2 antibodies
HK1131627B (zh) 来自ch5d12抗体的去免疫拮抗性抗人cd40单克隆抗体
CN1835976B (zh) 无糖基抗-cd154(cd40配体)抗体及其用途
AU2019217207B2 (en) Improved antagonistic anti-human CD40 monoclonal antibodies
WO2025031290A1 (zh) 抗ox40l抗体以及其用途
KR20240058075A (ko) Cd40을 특이적으로 식별하는 항체 및 이의 응용
MX2008005658A (en) Uses of anti-cd40 antibodies
HK1145690A (en) Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131627

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: FAST FORWARD PHARMACEUTICALS B. V.

Free format text: FORMER OWNER: PANGENETICS B.V.

Effective date: 20130625

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130625

Address after: Utrecht

Applicant after: PANGENETICS B. V.

Address before: Utrecht

Applicant before: Pangenetics B.V.

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1131627

Country of ref document: HK

TR01 Transfer of patent right

Effective date of registration: 20200724

Address after: New York, USA

Patentee after: Diabetes free company

Address before: Utrecht

Patentee before: Fast Forward Pharmaceuticals B.V.

TR01 Transfer of patent right